Navigation Links
Alere Inc. Announces Fourth Quarter 2010 Results
Date:2/17/2011

fourth quarter.
  • Adjusted free cash flow for the quarter was $78.4 million, reflecting adjusted cash flow from operations of $106.2 million, offset by capital expenditures of $27.8 million.
  • GAAP net loss of $1.0 billion attributable to common stockholders of Alere Inc. and respective net loss per common share of $12.24, compared to GAAP net loss of $3.1 million attributable to common stockholders of Alere Inc. and respective net loss per common share of $0.04, for the fourth quarter of 2009.  Fourth quarter 2010 GAAP net loss includes a $1.0 billion non-cash charge associated with the impairment of goodwill in our Health Management segment.
  • Adjusted cash basis net income per diluted common share from continuing operations of $0.71, compared to adjusted cash basis net income per diluted common share from continuing operations of $0.67, for the fourth quarter of 2009.

  • The Company's GAAP results for the fourth quarter of 2010 include amortization of $78.7 million, $6.9 million of stock-based compensation expense, $1.6 million of restructuring charges, $1.4 million of acquisition-related costs recorded in accordance with ASC 805, Business Combinations, a $1.0 billion non-cash charge associated with the impairment of goodwill in our Health Management segment, a $60.1 million compensation charge associated with our acquisition of minority shares, a $0.7 million write-down in the carrying value of a facility and $4.1 million of expense recorded for fair value adjustments to acquisition-related contingent consideration obligations, offset by a $0.3 million adjustment associated with the write-up to fair market value of inventory acquired in connection with acquisitions and a $0.3 million, net of tax, allocation of certain of the aforementioned charges to non-controlling stockholders.  The Company's GAAP results for the fourth quarter of 2009 include amortization of $71.9 million, $6.9 million of restructuring charges, $7.9
    '/>"/>

    SOURCE Alere Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine technology :

    1. Inverness Medical Innovations Changes Name to Alere
    2. Alere Inc. Schedules Conference Call for 10:00 a.m. ET July 28, 2010 to Discuss Second Quarter 2010 Results
    3. Alere and AirStrip Technologies - a Powerful Collaboration Brings Innovative Remote Patient Monitoring to Obstetrical Care
    4. Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes
    5. Alere Inc. Announces Pricing of Senior Subordinated Notes Offering; Offering Size Increased to $400.0 Million
    6. Alere to Attend the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010
    7. Alere to Attend the Lazard Capital Markets 7th Annual Healthcare Conference on November 17, 2010
    8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... at the American Association of Cancer Research ... on the potential for its lead product candidate ...
    (Date:5/29/2015)... INDIANAPOLIS , May 29, 2015  Eli Lilly ... AZN ) today announced that they have entered ... and preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint ... Lilly,s VEGF Receptor 2 antiangiogenic cancer medicine. The planned ... patients with advanced solid tumors. The Phase ...
    (Date:5/29/2015)... , May 29, 2015  World-renowned prostate surgeon and New ... on the benefit of MR/Ultrasound Fusion-Guided Biopsy for ... Prostate Cancer Center at Lenox Hill Hospital is ... System in New York City . We,ve ... risk prostate cancers. The use of an MRI makes for ...
    Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
    ... Mass., April 9, 2008 /PRNewswire-FirstCall/ - Echo,Therapeutics ... results,from its human feasibility study of the ... permeation medium for its,Symphony(TM) tCGM System, a ... development for diabetes home use and hospital ...
    ... April 8, 2008 The Association,for Professionals in ... L. Stricof, MT, MPH, of Albany, NY, has ... DeMille Achievement Award.,APIC presents the annual award to ... the ideals of Carole DeMille, a pioneer,in infection ...
    Cached Medicine Technology:Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 4Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 5New York Infection Prevention Expert Named Recipient of Carole DeMille Award 2
    (Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
    (Date:5/29/2015)... California (PRWEB) May 29, 2015 A group ... and have joined the national effort to teach this “new ... in the U.S. have been “sickened” by the recent implementation ... love it or hate it, Common Core is now a ... of Columbia. Parents are now seeking ways to improve ...
    (Date:5/29/2015)... May 29, 2015 Intermountain ... partnered with Stratus Video Interpreting ... facilitate better communication and timely care for ... hearing loss. Stratus’ video remote interpreting (VRI) ... enabling staff to quickly access qualified medical ...
    (Date:5/29/2015)... The print component of “Skin Health” ... approximately 250,000 and an estimated readership of 750,000. The ... media strategy, and across a network of top news ... of the campaign, click here. , Lucy ... the actress, model and producer details her skin care ...
    (Date:5/29/2015)... NY (PRWEB) May 29, 2015 Mediaplanet ... the “beauty of protection”. Skin Health is a ... Today within the markets of New York, Los Angeles, ... estimated 750,000 readers. Its digital counterpart will reach a ... hubs. To read more the Skin Health campaign and ...
    Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Doctors Discover a Cure for the Common Core 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2
    ... Finding challenges conventional theory on how immune system responds ... -- Immune system T-cells don,t begin to multiply until ... that changes current thinking about how the immune system ... Institute in La Jolla, Calif., said this delay in ...
    ... More at Risk than Adults, OAKBROOK TERRACE, ... and administered to children in health care,facilities are ... errors,according to a Joint Commission alert issued today ... Sentinel Event Alert addresses pediatric,medication errors, and urges ...
    ... of doctors around the United States walk a tightrope stretched ... the risk of abetting illegal and life-destroying drug addiction and ... , They walk this tightrope every time a patient asks ... as Oxycontin or Vicodin. These drugs have eased the pain ...
    ... RENO, Nev., April 10 Microflex Corporation, a ... gloves, and a,subsidiary of Barrier Safe Solutions International, ... non-latex gloves -- Tranquility(TM), a white,examination glove that ... Tranquility(TM) gloves conform to the hand allowing ...
    ... new report from Packaged Facts,Pet Insurance in North America, ... pet insurance during the next five years,placing sales as ... consistent,with soaring revenues in the overall pet market due ... the health and wellness of their,beloved furry family members. ...
    ... Osteoporosis,Foundation (NOF) has partnered with CESLIE - The ... women - a dynamic mother-daughter trio -,for their ... prevention. Joan Rivers, Melissa Rivers, Jill Eikenberry,Janet Hubert, ... Ceslie,Armstrong will host the cocktail soiree and networking ...
    Cached Medicine News:Health News:T-Cell Duplication Delayed Up to 3 Days After Infection 2Health News:Joint Commission Alert: Prevent Pediatric Medication Errors 2Health News:Joint Commission Alert: Prevent Pediatric Medication Errors 3Health News:Study shows doctor's offices can help stem abuse of Oxycontin, other narcotic painkillers 2Health News:Study shows doctor's offices can help stem abuse of Oxycontin, other narcotic painkillers 3Health News:Study shows doctor's offices can help stem abuse of Oxycontin, other narcotic painkillers 4Health News:Microflex Introduces Tranquility(TM) White Nitrile Gloves 2Health News:North America Primed for Pet Insurance Market Expansion and Expecting $1.1 Billion by 2012 2Health News:National Osteoporosis Foundation and CESLIE - The Women's Network Honor LeFrak Mother and Daughters for Commitment to Bone Health and New York Community 2
    Inquire...
    Inquire...
    ... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
    ... the most powerful, productive ... and rich in features, ... a comprehensive authoring environment ... custom interactive multimedia content ...
    Medicine Products: